Fierce Pharma

NOVEMBER 1, 2023

A few months ago, Fierce Pharma asked employees working in the biopharma industry to use photographs to tell their stories during the pandemic. After wreaking havoc on a pandemic level for more than three years, COVID-19 has entered its first endemic season. | Now, we’re showcasing those precious memories here.

Biopharma 192

Biopharma Pharma 192

Fierce Pharma

MAY 29, 2024

Already weathering the complex biopharma landscape in the U.S. | A tsunami of regulations will require biopharma to look to the high ground of knowledgeable partners

Biopharma 130

Biopharma 130

Fierce Pharma

JUNE 14, 2023

billion buyout of Horizon Therapeutics has raised concerns that the United States’ antitrust watchdog is tightening the screws on major M&A moves in the biopharma industry. An FTC lawsuit aimed at blocking Amgen’s $27.8 billion buyout o | An FTC lawsuit aimed at blocking Amgen’s $27.8

Biopharma 292

Biopharma 292

Fierce Pharma

MARCH 21, 2023

Biopharma industry lobbies for tax breaks related to US-based manufacturing kdunleavy Tue, 03/21/2023 - 11:14

Biopharma 261

Biopharma Manufacturing 261

Fierce Pharma

JANUARY 16, 2024

A USA Today review of millions of Glassdoor ratings found that employees in the biopharma industry are the most satisfied with their pay compared with other fields. 2023 was riddled with labor strikes across industries as workers lobbied for higher pay amid economic headwinds that shook up the global economy. |

Biopharma 246

Biopharma 246

Fierce Pharma

MAY 16, 2023

FTC seeks to block Amgen's $28B Horizon buy in 'broadly negative' move for biopharma M&A: report aliu Tue, 05/16/2023 - 09:41

Biopharma 293

Biopharma 293

Fierce Pharma

MAY 22, 2023

Pfizer, Moderna among many biopharma giants to post Q1 sales declines, as Novo Nordisk led growth charge kdunleavy Mon, 05/22/2023 - 13:04

Biopharma 295

Biopharma Sales 295

Fierce Pharma

SEPTEMBER 14, 2023

Amid the Federal Trade Commission's (FTC's) campaign to bolster scrutiny around large biopharma M&A deals, the agency is now taking a closer look at patent gamesmanship. |

Biopharma 245

Biopharma Pharmaceutical 245

Fierce Pharma

JUNE 26, 2023

But there was no evidence of the slide in biopharma where pay increases were plentiful. There was a decline in CEO compensation overall in 2022.

Biopharma 176

Biopharma 176

European Pharmaceutical Review

DECEMBER 30, 2023

The past 12 months has seen significant growth in global mergers and acquisitions (M&A) within the biopharma sector. This activity is expected to continue in 2024, with increasing need for biopharma to access innovation through collaboration and dealmaking to offset looming patent challenges. “In

Biopharma 105

Biopharma Marketing Prospecting Pharmaceutical 105

Zymewire

OCTOBER 15, 2024

In our Q3 2024 biopharma recap, we dive into the latest trends in funding, clinical trial activity, and therapeutic focus areas across the industry. With updated data on regional funding shifts and insights into the evolving biopharma landscape, this report will help CROs and CDMOs refine their strategies as they prepare for 2025.

Biopharma 52

Biopharma FDA 52

pharmaphorum

AUGUST 23, 2024

Zenas BioPharma has filed an initial public offering in the US seeking $100m+ for obexelimab, a therapy for rare disease IgG4-RD in phase 3

Biopharma 100

Biopharma 100

Fierce Pharma

DECEMBER 20, 2022

2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning products. Tue, 12/20/2022 - 13:39.

Biopharma 261

Biopharma 261

Fierce Pharma

NOVEMBER 18, 2024

may not rock the boat as much as feared for the biopharma industry. Robert F. | In a contrarian take offered by BMO Capital Markets' Evan Seigerman, the analyst said Robert F. Kennedy Jr.

Biopharma 293

Biopharma FDA Marketing 293

Fierce Pharma

MAY 9, 2023

Let's make a deal: Conditions are right for biopharma M&A to break out, analysts say kdunleavy Tue, 05/09/2023 - 10:18

Biopharma 242

Biopharma 242

Fierce Pharma

MAY 25, 2023

The Top Line': The 20 most influential people in biopharma, plus this week's headlines tcarey Thu, 05/25/2023 - 14:21

Biopharma 223

Biopharma 223

Fierce Pharma

DECEMBER 21, 2022

Tamiflu generics in short supply in latest chapter of biopharma's shortage saga. fkansteiner. Wed, 12/21/2022 - 08:40.

Biopharma 225

Biopharma 225

Fierce Pharma

APRIL 19, 2023

Alnylam, Intra-Cellular among analyst's top picks for M&A as biopharma dealmaking heats up aliu Wed, 04/19/2023 - 14:39

Biopharma 228

Biopharma 228

Pharmaceutical Technology

MARCH 8, 2024

Johnson & Johnson (J&J) has concluded the acquisition of Ambrx Biopharma in a transaction valued at approximately $2bn.

Biopharma 111

Biopharma 111

Fierce Pharma

MAY 9, 2023

We want your stories: Biopharma's collective memory of COVID—in photographs aliu Tue, 05/09/2023 - 14:56

Biopharma 157

Biopharma 157

Zymewire

JULY 24, 2024

As the second quarter of 2024 comes to a close, the biopharma landscape continues to evolve with dynamic shifts in funding, clinical trials, and innovative developments. Zymewire is back to provide you with a comprehensive digest of what's happened in Q2, to help inform smarter business decisions going forward.

Biopharma 52

Biopharma 52

European Pharmaceutical Review

JUNE 7, 2023

The global biopharma industry’s resilience has decreased since 2021, a report by Cytiva has found. Using feedback from 1250 pharma and biopharma executives in 22 countries, the research sought to find out how has the biopharma industry has evolved over the past two years and what areas the industry should seek to improve.

Biopharma 97

Biopharma Government Manufacturing Pharma 97

MedCity News

OCTOBER 3, 2023

Acquiring Point Biopharma gives Eli Lilly a pipeline of radiopharmaceuticals, including one for prostate cancer that could rival Novartis’s Pluvicto. The deal comes ahead of an expected Phase 3 data readout for that Point therapeutic candidate.

Biopharma 118

Biopharma Pharma 118

Fierce Pharma

MAY 18, 2023

The Top Line': 2023's biopharma layoffs, plus this week's headlines tcarey Thu, 05/18/2023 - 16:13

Biopharma 144

Biopharma 144

European Pharmaceutical Review

APRIL 17, 2023

A report on automation in the biopharma industr y has shown that the market is projected to grow at a compound annual growth rate (CAGR) of 5.7 Factors impacting the automation in the biopharma industry market The report found that 75 percent of pharmaceutical organisations want to use automated solutions more frequently.

Biopharma 98

Biopharma Manufacturing Pharmaceutical products Marketing 98

PharmaTech

JULY 23, 2024

The addition of BIOVECTRA’s biologics capabilities to accelerate drug development and manufacturing will allow Agilent to expand its end-to-end offerings for biopharma services.

Biopharma 59

Biopharma Manufacturing 59

MedCity News

FEBRUARY 16, 2024

It’s time for the biopharma industry to embrace end-to-end digitalization. Moving from spreadsheets to automated data collection and processing is far from easy, but it could revolutionize drug development.

Biopharma 112

Biopharma 112

European Pharmaceutical Review

JULY 7, 2023

New recommendations to boost the competitiveness in UK biopharma and Medtech sectors have been published by Imperial College London. Technological solutions and policy recommendations for government have been identified as a way to help make sectors such as biopharma and Medtech more innovative and increase their value added.

Competition 104

Competition Biopharma Government Manufacturing 104

Fierce Pharma

AUGUST 20, 2024

As House lawmakers prepare for a September vote on the controversial BIOSECURE Act, the House Select Committee on the CCP is expanding the scope of its scrutiny on China's biopharma ecosystem. |

Biopharma 333

Biopharma FDA 333

PharmExec

AUGUST 21, 2023

In this exclusive Q&A with Pharmaceutical Executive, Janice Chang, CEO of TransCelerate BioPharma, provides an inside look into her career journey, her work at the company, how the industry has changed in the last 10 years, as well as her thoughts on where the industry should put its efforts in clinical trials.

Biopharma 97

Biopharma Pharmaceutical 97

Fierce Pharma

JANUARY 23, 2023

Call for nominations: The most influential people in biopharma in 2023 esagonowsky Mon, 01/23/2023 - 14:32

Biopharma 130

Biopharma 130

European Pharmaceutical Review

SEPTEMBER 4, 2023

The biopharma company will be required to seek prior approval before acquiring related products. Divest to invest: the new normal in biopharma? The post FTC order could ease biopharma competition appeared first on European Pharmaceutical Review. The FTC has settled on a proposed consent order with Amgen Inc.

Competition 98

Competition Biopharma Pharmaceutical Government 98

PharmaVoice

JUNE 13, 2023

Collaboration is important along the entire spectrum and lifecycle of biopharma, and finding an effective partner is harder than it sounds.

Biopharma 106

Biopharma 106

PharmaTech

JANUARY 24, 2024

Under a new alliance, KBI Biopharma and Argonaut Manufacturing Services will combine their strengths to offer end-to-end biopharma development and CGMP manufacturing solutions.

Biopharma 98

Biopharma Manufacturing 98

MedCity News

AUGUST 21, 2023

Healthcare M&A deals are expected to pick up over the next few months, and one expert is predicting that the biopharma sector in particular will see especially robust activity.

Biopharma 98

Biopharma Marketing Healthcare Healthcare 98

MedCity News

JUNE 18, 2024

The post Cancer Biotech Day One Biopharma Expands to ADCs, Paying $55M to Nab a Phase 1-Ready Drug appeared first on MedCity News. Day One Biopharmaceuticals is adding an antibody drug conjugate to its pipeline, licensing rights to a molecule from MabCare Therapeutics.

Biopharma 109

Biopharma Pharma 109

PharmaTech

NOVEMBER 3, 2023

Pharmaceutical Technology Europe® spoke with Gustavo Ferrer from Dr. Ferrer BioPharma, a US company focused on innovative intranasal medications, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.

Biopharma 98

Biopharma Medical Pharmaceutical Marketing 98